BLCM Bellicum PharmaceuticalsWatchlist
About Bellicum Pharmaceuticals Company
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.
America's Top Cancer Research Agency: Developing a Drug That Kills All Solid Cancers
Glonway, August 2 | America's top cancer treatment and research agency, the City of Hope (City of Hope) National Medical Center, issued an announcement on Tuesday saying that in pre-clinical research, scientists at the agency developed a targeted chemotherapy drug that can kill all solid malignant tumors (cancer). The preclinical research mentioned in the announcement has been published in the journal “Cytochemical Biology” in the form of a paper. The drug mentioned earlier (AOH1996) is an oral small molecule PCNA (proliferative cell nuclear antigen) inhibitor used to inhibit tumor cell proliferation.
12 Health Care Stocks Moving In Friday's Intraday Session
GainersMinerva Surgical (NASDAQ:UTRS) shares increased by 111.8% to $0.42 during Friday's regular session. As of 13:30 EST, Minerva Surgical's stock is trading at a volume of 85.0 million, which is 38
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersAridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 98.9% to $0.37 during Wednesday's pre-market session. The market value of their outstanding shares is at $13.2 million. VistaGen Therape